Polartechnics finds partners for Cerviscreen

14 September 2008

Polartechnics, a health care firm specializing in developing, manufacturing and marketing devices for the detection of pre-cancer and cancer, is to partner with fellow Australian firms Genera Biosystems and Healthscope in the development and launch of cervical cancer test Cerviscreen.

Cerviscreen is Polartechnics' novel self-sampling device for human papillomavirus. Genera will be providing its PapType HPV detection and genotyping assay for use in the Cerviscreen system in Australia, Southeast Asia and Europe.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight